Currently, an ongoing phase III, multicenter, randomized, sham-controlled, double-blind trial is evaluating AT-04s efficacy and safety for endometriosis-related pain (dysmenorrhea, dyspareunia, chronic pelvic pain), with the primary outcome being the change in Numeric Rating Scale score at 16 weeks ( 4.5 Disease heterogeneity and subtype-specific therapeutic strategies Endometriosis exhibits significant clinical and biological heterogeneity, encompassing diverse anatomical subtypessuperficial peritoneal endometriosis (SPE), ovarian endometriomas (OMA), and deep infiltrating endometriosis (DIE)each with distinct pathophysiological features, symptom profiles, and fertility implications ( Table 1 )
This is not a paper that says GLP-1 medications are perfect and muscle loss is a myth
The GLP-1 market growth is driven by advancements in drug formulations, particularly the development of oral and long-acting therapies
Start tirzepatide on your next scheduled injection day